Global Neurodegenerative Diseases Therapeutics Market 2025-2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	251 Pages	TechNavio	April, 2025	INF20007296

Best Price Guarantee
Price	from $2,500
Length	251 Pages
Publisher	TechNavio
Published Date	April, 2025
SKU	INF20007296

Neurodegenerative Diseases Therapeutics Market 2025-2029

The neurodegenerative diseases therapeutics market is forecasted to grow by USD 24852.2 mn during 2024-2029, accelerating at a CAGR of 9.1% during the forecast period. The report on the neurodegenerative diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by strong drug development pipeline, high research funding on neurodegenerative diseases, and availability of highly sensitive diagnostic modalities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's neurodegenerative diseases therapeutics market is segmented as below:

By Indication

Multiple sclerosis
Alzheimers disease
Parkinsons disease
Huntingtons disease
Others

By Drug Class

Immunomodulators
Interferons
Decarboxylase inhibitors
Dopamine agonists
Others

By Route Of Administration

Oral
Injection
Transdermal

By End-user

Hospital pharmacy
Retail pharmacy
Online pharmacy

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the increase in aging population as one of the prime reasons driving the neurodegenerative diseases therapeutics market growth during the next few years. Also, improved understanding of genetic basis and molecular pathology of neurodegenerative diseases and high economic burden will lead to sizable demand in the market.

The report on the neurodegenerative diseases therapeutics market covers the following areas:

Neurodegenerative Diseases Therapeutics Market sizing
Neurodegenerative Diseases Therapeutics Market forecast
Neurodegenerative Diseases Therapeutics Market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neurodegenerative diseases therapeutics market vendors that include AB Science SA, AbbVie Inc., Acadia Pharmaceuticals Inc., AstraZeneca Plc, Biogen Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson Services Inc., Merck and Co. Inc., Mitsubishi Chemical Corp., Novartis AG, Pfizer Inc., Sanofi SA, and Teva Pharmaceutical Industries Ltd.. Also, the neurodegenerative diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary: 1.1 Market overview; Executive Summary - Chart on Market Overview; Executive Summary - Data Table on Market Overview; Executive Summary - Chart on Global Market Characteristics; Executive Summary - Chart on Market By Geographical Landscape; Executive Summary - Chart on Market Segmentation by Indication; Executive Summary - Chart on Market Segmentation by Drug Class; Executive Summary - Chart on Market Segmentation by Route of Administration; Executive Summary - Chart on Market Segmentation by End-user; Executive Summary - Chart on Incremental Growth; Executive Summary - Data Table on Incremental Growth; Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis: 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; 2.2 Criticality of inputs and Factors of differentiation; Overview on criticality of inputs and factors of differentiation; 2.3 Factors of disruption; Overview on factors of disruption; 2.4 Impact of drivers and challenges; Impact of drivers and challenges in 2024 and 2029
3 Market Landscape: 3.1 Market ecosystem; Parent Market; Data Table on - Parent Market; 3.2 Market characteristics; Market characteristics analysis; 3.3 Value chain analysis; Value chain analysis
4 Market Sizing: 4.1 Market definition; Offerings of companies included in the market definition; 4.2 Market segment analysis; Market segments; 4.3 Market size 2024; 4.4 Market outlook: Forecast for 2024-2029; Chart on Global - Market size and forecast 2024-2029 ($ million); Data Table on Global - Market size and forecast 2024-2029 ($ million); Chart on Global Market: Year-over-year growth 2024-2029 (%); Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size: 5.1 Global Neurodegenerative Diseases Therapeutics Market 2019 - 2023; Historic Market Size - Data Table on Global Neurodegenerative Diseases Therapeutics Market 2019 - 2023 ($ million); 5.2 Indication segment analysis 2019 - 2023; Historic Market Size - Indication Segment 2019 - 2023 ($ million); 5.3 Drug Class segment analysis 2019 - 2023; Historic Market Size - Drug Class Segment 2019 - 2023 ($ million); 5.4 Route of Administration segment analysis 2019 - 2023; Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million); 5.5 End-user segment analysis 2019 - 2023; Historic Market Size - End-user Segment 2019 - 2023 ($ million); 5.6 Geography segment analysis 2019 - 2023; Historic Market Size - Geography Segment 2019 - 2023 ($ million); 5.7 Country segment analysis 2019 - 2023; Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis: 6.1 Impact of AI in global neurodegenerative diseases therapeutics market
7 Five Forces Analysis: 7.1 Five forces summary; Five forces analysis - Comparison between 2024 and 2029; 7.2 Bargaining power of buyers; Bargaining power of buyers - Impact of key factors 2024 and 2029; 7.3 Bargaining power of suppliers; Bargaining power of suppliers - Impact of key factors in 2024 and 2029; 7.4 Threat of new entrants; Threat of new entrants - Impact of key factors in 2024 and 2029; 7.5 Threat of substitutes; Threat of substitutes - Impact of key factors in 2024 and 2029; 7.6 Threat of rivalry; Threat of rivalry - Impact of key factors in 2024 and 2029; 7.7 Market condition; Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Indication: 8.1 Market segments; Chart on Indication - Market share 2024-2029 (%); Data Table on Indication - Market share 2024-2029 (%); 8.2 Comparison by Indication; Chart on Comparison by Indication; Data Table on Comparison by Indication; 8.3 Multiple sclerosis - Market size and forecast 2024-2029; Chart on Multiple sclerosis - Market size and forecast 2024-2029 ($ million); Data Table on Multiple sclerosis - Market size and forecast 2024-2029 ($ million); Chart on Multiple sclerosis - Year-over-year growth 2024-2029 (%); Data Table on Multiple sclerosis - Year-over-year growth 2024-2029 (%); 8.4 Alzheimers disease - Market size and forecast 2024-2029; Chart on Alzheimers disease - Market size and forecast 2024-2029 ($ million); Data Table on Alzheimers disease - Market size and forecast 2024-2029 ($ million); Chart on Alzheimers disease - Year-over-year growth 2024-2029 (%); Data Table on Alzheimers disease - Year-over-year growth 2024-2029 (%); 8.5 Parkinsons disease - Market size and forecast 2024-2029; Chart on Parkinsons disease - Market size and forecast 2024-2029 ($ million); Data Table on Parkinsons disease - Market size and forecast 2024-2029 ($ million); Chart on Parkinsons disease - Year-over-year growth 2024-2029 (%); Data Table on Parkinsons disease - Year-over-year growth 2024-2029 (%); 8.6 Huntingtons disease - Market size and forecast 2024-2029; Chart on Huntingtons disease - Market size and forecast 2024-2029 ($ million); Data Table on Huntingtons disease - Market size and forecast 2024-2029 ($ million); Chart on Huntingtons disease - Year-over-year growth 2024-2029 (%); Data Table on Huntingtons disease - Year-over-year growth 2024-2029 (%); 8.7 Others - Market size and forecast 2024-2029; Chart on Others - Market size and forecast 2024-2029 ($ million); Data Table on Others - Market size and forecast 2024-2029 ($ million); Chart on Others - Year-over-year growth 2024-2029 (%); Data Table on Others - Year-over-year growth 2024-2029 (%); 8.8 Market opportunity by Indication; Market opportunity by Indication ($ million); Data Table on Market opportunity by Indication ($ million)
9 Market Segmentation by Drug Class: 9.1 Market segments; Chart on Drug Class - Market share 2024-2029 (%); Data Table on Drug Class - Market share 2024-2029 (%); 9.2 Comparison by Drug Class; Chart on Comparison by Drug Class; Data Table on Comparison by Drug Class; 9.3 Immunomodulators - Market size and forecast 2024-2029; Chart on Immunomodulators - Market size and forecast 2024-2029 ($ million); Data Table on Immunomodulators - Market size and forecast 2024-2029 ($ million); Chart on Immunomodulators - Year-over-year growth 2024-2029 (%); Data Table on Immunomodulators - Year-over-year growth 2024-2029 (%); 9.4 Interferons - Market size and forecast 2024-2029; Chart on Interferons - Market size and forecast 2024-2029 ($ million); Data Table on Interferons - Market size and forecast 2024-2029 ($ million); Chart on Interferons - Year-over-year growth 2024-2029 (%); Data Table on Interferons - Year-over-year growth 2024-2029 (%); 9.5 Decarboxylase inhibitors - Market size and forecast 2024-2029; Chart on Decarboxylase inhibitors - Market size and forecast 2024-2029 ($ million); Data Table on Decarboxylase inhibitors - Market size and forecast 2024-2029 ($ million); Chart on Decarboxylase inhibitors - Year-over-year growth 2024-2029 (%); Data Table on Decarboxylase inhibitors - Year-over-year growth 2024-2029 (%); 9.6 Dopamine agonists - Market size and forecast 2024-2029; Chart on Dopamine agonists - Market size and forecast 2024-2029 ($ million); Data Table on Dopamine agonists - Market size and forecast 2024-2029 ($ million); Chart on Dopamine agonists - Year-over-year growth 2024-2029 (%); Data Table on Dopamine agonists - Year-over-year growth 2024-2029 (%); 9.7 Others - Market size and forecast 2024-2029; Chart on Others - Market size and forecast 2024-2029 ($ million); Data Table on Others - Market size and forecast 2024-2029 ($ million); Chart on Others - Year-over-year growth 2024-2029 (%); Data Table on Others - Year-over-year growth 2024-2029 (%); 9.8 Market opportunity by Drug Class; Market opportunity by Drug Class ($ million); Data Table on Market opportunity by Drug Class ($ million)
10 Market Segmentation by Route of Administration: 10.1 Market segments; Chart on Route of Administration - Market share 2024-2029 (%); Data Table on Route of Administration - Market share 2024-2029 (%); 10.2 Comparison by Route of Administration; Chart on Comparison by Route of Administration; Data Table on Comparison by Route of Administration; 10.3 Oral - Market size and forecast 2024-2029; Chart on Oral - Market size and forecast 2024-2029 ($ million); Data Table on Oral - Market size and forecast 2024-2029 ($ million); Chart on Oral - Year-over-year growth 2024-2029 (%); Data Table on Oral - Year-over-year growth 2024-2029 (%); 10.4 Injection - Market size and forecast 2024-2029; Chart on Injection - Market size and forecast 2024-2029 ($ million); Data Table on Injection - Market size and forecast 2024-2029 ($ million); Chart on Injection - Year-over-year growth 2024-2029 (%); Data Table on Injection - Year-over-year growth 2024-2029 (%); 10.5 Transdermal - Market size and forecast 2024-2029; Chart on Transdermal - Market size and forecast 2024-2029 ($ million); Data Table on Transdermal - Market size and forecast 2024-2029 ($ million); Chart on Transdermal - Year-over-year growth 2024-2029 (%); Data Table on Transdermal - Year-over-year growth 2024-2029 (%); 10.6 Market opportunity by Route of Administration; Market opportunity by Route of Administration ($ million); Data Table on Market opportunity by Route of Administration ($ million)
11 Market Segmentation by End-user: 11.1 Market segments; Chart on End-user - Market share 2024-2029 (%); Data Table on End-user - Market share 2024-2029 (%); 11.2 Comparison by End-user; Chart on Comparison by End-user; Data Table on Comparison by End-user; 11.3 Hospital pharmacy - Market size and forecast 2024-2029; Chart on Hospital pharmacy - Market size and forecast 2024-2029 ($ million); Data Table on Hospital pharmacy - Market size and forecast 2024-2029 ($ million); Chart on Hospital pharmacy - Year-over-year growth 2024-2029 (%); Data Table on Hospital pharmacy - Year-over-year growth 2024-2029 (%); 11.4 Retail pharmacy - Market size and forecast 2024-2029; Chart on Retail pharmacy - Market size and forecast 2024-2029 ($ million); Data Table on Retail pharmacy - Market size and forecast 2024-2029 ($ million); Chart on Retail pharmacy - Year-over-year growth 2024-2029 (%); Data Table on Retail pharmacy - Year-over-year growth 2024-2029 (%); 11.5 Online pharmacy - Market size and forecast 2024-2029; Chart on Online pharmacy - Market size and forecast 2024-2029 ($ million); Data Table on Online pharmacy - Market size and forecast 2024-2029 ($ million); Chart on Online pharmacy - Year-over-year growth 2024-2029 (%); Data Table on Online pharmacy - Year-over-year growth 2024-2029 (%); 11.6 Market opportunity by End-user; Market opportunity by End-user ($ million); Data Table on Market opportunity by End-user ($ million)
12 Customer Landscape: 12.1 Customer landscape overview; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
13 Geographic Landscape: 13.1 Geographic segmentation; Chart on Market share By Geographical Landscape 2024-2029 (%); Data Table on Market share By Geographical Landscape 2024-2029 (%); 13.2 Geographic comparison; Chart on Geographic comparison; Data Table on Geographic comparison; 13.3 North America - Market size and forecast 2024-2029; Chart on North America - Market size and forecast 2024-2029 ($ million); Data Table on North America - Market size and forecast 2024-2029 ($ million); Chart on North America - Year-over-year growth 2024-2029 (%); Data Table on North America - Year-over-year growth 2024-2029 (%); 13.4 Europe - Market size and forecast 2024-2029; Chart on Europe - Market size and forecast 2024-2029 ($ million); Data Table on Europe - Market size and forecast 2024-2029 ($ million); Chart on Europe - Year-over-year growth 2024-2029 (%); Data Table on Europe - Year-over-year growth 2024-2029 (%); 13.5 Asia - Market size and forecast 2024-2029; Chart on Asia - Market size and forecast 2024-2029 ($ million); Data Table on Asia - Market size and forecast 2024-2029 ($ million); Chart on Asia - Year-over-year growth 2024-2029 (%); Data Table on Asia - Year-over-year growth 2024-2029 (%); 13.6 Rest of World (ROW) - Market size and forecast 2024-2029; Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million); Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million); Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%); Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%); 13.7 US - Market size and forecast 2024-2029; Chart on US - Market size and forecast 2024-2029 ($ million); Data Table on US - Market size and forecast 2024-2029 ($ million); Chart on US - Year-over-year growth 2024-2029 (%); Data Table on US - Year-over-year growth 2024-2029 (%); 13.8 Germany - Market size and forecast 2024-2029; Chart on Germany - Market size and forecast 2024-2029 ($ million); Data Table on Germany - Market size and forecast 2024-2029 ($ million); Chart on Germany - Year-over-year growth 2024-2029 (%); Data Table on Germany - Year-over-year growth 2024-2029 (%); 13.9 Canada - Market size and forecast 2024-2029; Chart on Canada - Market size and forecast 2024-2029 ($ million); Data Table on Canada - Market size and forecast 2024-2029 ($ million); Chart on Canada - Year-over-year growth 2024-2029 (%); Data Table on Canada - Year-over-year growth 2024-2029 (%); 13.10 China - Market size and forecast 2024-2029; Chart on China - Market size and forecast 2024-2029 ($ million); Data Table on China - Market size and forecast 2024-2029 ($ million); Chart on China - Year-over-year growth 2024-2029 (%); Data Table on China - Year-over-year growth 2024-2029 (%); 13.11 Japan - Market size and forecast 2024-2029; Chart on Japan - Market size and forecast 2024-2029 ($ million); Data Table on Japan - Market size and forecast 2024-2029 ($ million); Chart on Japan - Year-over-year growth 2024-2029 (%); Data Table on Japan - Year-over-year growth 2024-2029 (%); 13.12 UK - Market size and forecast 2024-2029; Chart on UK - Market size and forecast 2024-2029 ($ million); Data Table on UK - Market size and forecast 2024-2029 ($ million); Chart on UK - Year-over-year growth 2024-2029 (%); Data Table on UK - Year-over-year growth 2024-2029 (%); 13.13 France - Market size and forecast 2024-2029; Chart on France - Market size and forecast 2024-2029 ($ million); Data Table on France - Market size and forecast 2024-2029 ($ million); Chart on France - Year-over-year growth 2024-2029 (%); Data Table on France - Year-over-year growth 2024-2029 (%); 13.14 India - Market size and forecast 2024-2029; Chart on India - Market size and forecast 2024-2029 ($ million); Data Table on India - Market size and forecast 2024-2029 ($ million); Chart on India - Year-over-year growth 2024-2029 (%); Data Table on India - Year-over-year growth 2024-2029 (%); 13.15 Italy - Market size and forecast 2024-2029; Chart on Italy - Market size and forecast 2024-2029 ($ million); Data Table on Italy - Market size and forecast 2024-2029 ($ million); Chart on Italy - Year-over-year growth 2024-2029 (%); Data Table on Italy - Year-over-year growth 2024-2029 (%); 13.16 South Korea - Market size and forecast 2024-2029; Chart on South Korea - Market size and forecast 2024-2029 ($ million); Data Table on South Korea - Market size and forecast 2024-2029 ($ million); Chart on South Korea - Year-over-year growth 2024-2029 (%); Data Table on South Korea - Year-over-year growth 2024-2029 (%); 13.17 Market opportunity By Geographical Landscape; Market opportunity By Geographical Landscape ($ million); Data Tables on Market opportunity By Geographical Landscape ($ million)
14 Drivers, Challenges, and Opportunity/Restraints: 14.1 Market drivers; 14.2 Market challenges; 14.3 Impact of drivers and challenges; Impact of drivers and challenges in 2024 and 2029; 14.4 Market opportunities/restraints
15 Competitive Landscape: 15.1 Overview; 15.2 Competitive Landscape; Overview on criticality of inputs and factors of differentiation; 15.3 Landscape disruption; Overview on factors of disruption; 15.4 Industry risks; Impact of key risks on business
16 Competitive Analysis: 16.1 Companies profiled; Companies covered; 16.2 Company ranking index; Company ranking index; 16.3 Market positioning of companies; Matrix on companies position and classification; 16.4 AB Science SA; AB Science SA - Overview; AB Science SA - Product / Service; AB Science SA - Key offerings; SWOT; 16.5 AbbVie Inc.; AbbVie Inc. - Overview; AbbVie Inc. - Product / Service; AbbVie Inc. - Key news; AbbVie Inc. - Key offerings; SWOT; 16.6 Acadia Pharmaceuticals Inc.; Acadia Pharmaceuticals Inc. - Overview; Acadia Pharmaceuticals Inc. - Product / Service; Acadia Pharmaceuticals Inc. - Key offerings; SWOT; 16.7 AstraZeneca Plc; AstraZeneca Plc - Overview; AstraZeneca Plc - Product / Service; AstraZeneca Plc - Key news; AstraZeneca Plc - Key offerings; SWOT; 16.8 Biogen Inc.; Biogen Inc. - Overview; Biogen Inc. - Product / Service; Biogen Inc. - Key offerings; SWOT; 16.9 F. Hoffmann La Roche Ltd.; F. Hoffmann La Roche Ltd. - Overview; F. Hoffmann La Roche Ltd. - Business segments; F. Hoffmann La Roche Ltd. - Key news; F. Hoffmann La Roche Ltd. - Key offerings; F. Hoffmann La Roche Ltd. - Segment focus; SWOT; 16.10 GlaxoSmithKline Plc; GlaxoSmithKline Plc - Overview; GlaxoSmithKline Plc - Business segments; GlaxoSmithKline Plc - Key news; GlaxoSmithKline Plc - Key offerings; GlaxoSmithKline Plc - Segment focus; SWOT; 16.11 H Lundbeck AS; H Lundbeck AS - Overview; H Lundbeck AS - Product / Service; H Lundbeck AS - Key offerings; SWOT; 16.12 Johnson and Johnson Services Inc.; Johnson and Johnson Services Inc. - Overview; Johnson and Johnson Services Inc. - Business segments; Johnson and Johnson Services Inc. - Key news; Johnson and Johnson Services Inc. - Key offerings; Johnson and Johnson Services Inc. - Segment focus; SWOT; 16.13 Merck and Co. Inc.; Merck and Co. Inc. - Overview; Merck and Co. Inc. - Business segments; Merck and Co. Inc. - Key news; Merck and Co. Inc. - Key offerings; Merck and Co. Inc. - Segment focus; SWOT; 16.14 Mitsubishi Chemical Corp.; Mitsubishi Chemical Corp. - Overview; Mitsubishi Chemical Corp. - Business segments; Mitsubishi Chemical Corp. - Key offerings; Mitsubishi Chemical Corp. - Segment focus; SWOT; 16.15 Novartis AG; Novartis AG - Overview; Novartis AG - Business segments; Novartis AG - Key news; Novartis AG - Key offerings; Novartis AG - Segment focus; SWOT; 16.16 Pfizer Inc.; Pfizer Inc. - Overview; Pfizer Inc. - Product / Service; Pfizer Inc. - Key news; Pfizer Inc. - Key offerings; SWOT; 16.17 Sanofi SA; Sanofi SA - Overview; Sanofi SA - Business segments; Sanofi SA - Key news; Sanofi SA - Key offerings; Sanofi SA - Segment focus; SWOT; 16.18 Teva Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd. - Overview; Teva Pharmaceutical Industries Ltd. - Business segments; Teva Pharmaceutical Industries Ltd. - Key news; Teva Pharmaceutical Industries Ltd. - Key offerings; Teva Pharmaceutical Industries Ltd. - Segment focus; SWOT
17 Appendix: 17.1 Scope of the report; 17.2 Inclusions and exclusions checklist; Inclusions checklist; Exclusions checklist; 17.3 Currency conversion rates for US$; Currency conversion rates for US$; 17.4 Research methodology; Research methodology; 17.5 Data procurement; Information sources; 17.6 Data validation; Data validation; 17.7 Validation techniques employed for market sizing; Validation techniques employed for market sizing; 17.8 Data synthesis; Data synthesis; 17.9 360 degree market analysis; 360 degree market analysis; 17.10 List of abbreviations; List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market By Geographical Landscape; Exhibits5: Executive Summary - Chart on Market Segmentation by Indication; Exhibits6: Executive Summary - Chart on Market Segmentation by Drug Class; Exhibits7: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibits8: Executive Summary - Chart on Market Segmentation by End-user; Exhibits9: Executive Summary - Chart on Incremental Growth; Exhibits10: Executive Summary - Data Table on Incremental Growth; Exhibits11: Executive Summary - Chart on Company Market Positioning; Exhibits12: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits13: Overview on criticality of inputs and factors of differentiation; Exhibits14: Overview on factors of disruption; Exhibits15: Impact of drivers and challenges in 2024 and 2029; Exhibits16: Parent Market; Exhibits17: Data Table on - Parent Market; Exhibits18: Market characteristics analysis; Exhibits19: Value chain analysis; Exhibits20: Offerings of companies included in the market definition; Exhibits21: Market segments; Exhibits22: Chart on Global - Market size and forecast 2024-2029 ($ million); Exhibits23: Data Table on Global - Market size and forecast 2024-2029 ($ million); Exhibits24: Chart on Global Market: Year-over-year growth 2024-2029 (%); Exhibits25: Data Table on Global Market: Year-over-year growth 2024-2029 (%); Exhibits26: Historic Market Size - Data Table on Global Neurodegenerative Diseases Therapeutics Market 2019 - 2023 ($ million); Exhibits27: Historic Market Size - Indication Segment 2019 - 2023 ($ million); Exhibits28: Historic Market Size - Drug Class Segment 2019 - 2023 ($ million); Exhibits29: Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million); Exhibits30: Historic Market Size - End-user Segment 2019 - 2023 ($ million); Exhibits31: Historic Market Size - Geography Segment 2019 - 2023 ($ million); Exhibits32: Historic Market Size - Country Segment 2019 - 2023 ($ million); Exhibits33: Five forces analysis - Comparison between 2024 and 2029; Exhibits34: Bargaining power of buyers - Impact of key factors 2024 and 2029; Exhibits35: Bargaining power of suppliers - Impact of key factors in 2024 and 2029; Exhibits36: Threat of new entrants - Impact of key factors in 2024 and 2029; Exhibits37: Threat of substitutes - Impact of key factors in 2024 and 2029; Exhibits38: Threat of rivalry - Impact of key factors in 2024 and 2029; Exhibits39: Chart on Market condition - Five forces 2024 and 2029; Exhibits40: Chart on Indication - Market share 2024-2029 (%); Exhibits41: Data Table on Indication - Market share 2024-2029 (%); Exhibits42: Chart on Comparison by Indication; Exhibits43: Data Table on Comparison by Indication; Exhibits44: Chart on Multiple sclerosis - Market size and forecast 2024-2029 ($ million); Exhibits45: Data Table on Multiple sclerosis - Market size and forecast 2024-2029 ($ million); Exhibits46: Chart on Multiple sclerosis - Year-over-year growth 2024-2029 (%); Exhibits47: Data Table on Multiple sclerosis - Year-over-year growth 2024-2029 (%); Exhibits48: Chart on Alzheimers disease - Market size and forecast 2024-2029 ($ million); Exhibits49: Data Table on Alzheimers disease - Market size and forecast 2024-2029 ($ million); Exhibits50: Chart on Alzheimers disease - Year-over-year growth 2024-2029 (%); Exhibits51: Data Table on Alzheimers disease - Year-over-year growth 2024-2029 (%); Exhibits52: Chart on Parkinsons disease - Market size and forecast 2024-2029 ($ million); Exhibits53: Data Table on Parkinsons disease - Market size and forecast 2024-2029 ($ million); Exhibits54: Chart on Parkinsons disease - Year-over-year growth 2024-2029 (%); Exhibits55: Data Table on Parkinsons disease - Year-over-year growth 2024-2029 (%); Exhibits56: Chart on Huntingtons disease - Market size and forecast 2024-2029 ($ million); Exhibits57: Data Table on Huntingtons disease - Market size and forecast 2024-2029 ($ million); Exhibits58: Chart on Huntingtons disease - Year-over-year growth 2024-2029 (%); Exhibits59: Data Table on Huntingtons disease - Year-over-year growth 2024-2029 (%); Exhibits60: Chart on Others - Market size and forecast 2024-2029 ($ million); Exhibits61: Data Table on Others - Market size and forecast 2024-2029 ($ million); Exhibits62: Chart on Others - Year-over-year growth 2024-2029 (%); Exhibits63: Data Table on Others - Year-over-year growth 2024-2029 (%); Exhibits64: Market opportunity by Indication ($ million); Exhibits65: Data Table on Market opportunity by Indication ($ million); Exhibits66: Chart on Drug Class - Market share 2024-2029 (%); Exhibits67: Data Table on Drug Class - Market share 2024-2029 (%); Exhibits68: Chart on Comparison by Drug Class; Exhibits69: Data Table on Comparison by Drug Class; Exhibits70: Chart on Immunomodulators - Market size and forecast 2024-2029 ($ million); Exhibits71: Data Table on Immunomodulators - Market size and forecast 2024-2029 ($ million); Exhibits72: Chart on Immunomodulators - Year-over-year growth 2024-2029 (%); Exhibits73: Data Table on Immunomodulators - Year-over-year growth 2024-2029 (%); Exhibits74: Chart on Interferons - Market size and forecast 2024-2029 ($ million); Exhibits75: Data Table on Interferons - Market size and forecast 2024-2029 ($ million); Exhibits76: Chart on Interferons - Year-over-year growth 2024-2029 (%); Exhibits77: Data Table on Interferons - Year-over-year growth 2024-2029 (%); Exhibits78: Chart on Decarboxylase inhibitors - Market size and forecast 2024-2029 ($ million); Exhibits79: Data Table on Decarboxylase inhibitors - Market size and forecast 2024-2029 ($ million); Exhibits80: Chart on Decarboxylase inhibitors - Year-over-year growth 2024-2029 (%); Exhibits81: Data Table on Decarboxylase inhibitors - Year-over-year growth 2024-2029 (%); Exhibits82: Chart on Dopamine agonists - Market size and forecast 2024-2029 ($ million); Exhibits83: Data Table on Dopamine agonists - Market size and forecast 2024-2029 ($ million); Exhibits84: Chart on Dopamine agonists - Year-over-year growth 2024-2029 (%); Exhibits85: Data Table on Dopamine agonists - Year-over-year growth 2024-2029 (%); Exhibits86: Chart on Others - Market size and forecast 2024-2029 ($ million); Exhibits87: Data Table on Others - Market size and forecast 2024-2029 ($ million); Exhibits88: Chart on Others - Year-over-year growth 2024-2029 (%); Exhibits89: Data Table on Others - Year-over-year growth 2024-2029 (%); Exhibits90: Market opportunity by Drug Class ($ million); Exhibits91: Data Table on Market opportunity by Drug Class ($ million); Exhibits92: Chart on Route of Administration - Market share 2024-2029 (%); Exhibits93: Data Table on Route of Administration - Market share 2024-2029 (%); Exhibits94: Chart on Comparison by Route of Administration; Exhibits95: Data Table on Comparison by Route of Administration; Exhibits96: Chart on Oral - Market size and forecast 2024-2029 ($ million); Exhibits97: Data Table on Oral - Market size and forecast 2024-2029 ($ million); Exhibits98: Chart on Oral - Year-over-year growth 2024-2029 (%); Exhibits99: Data Table on Oral - Year-over-year growth 2024-2029 (%); Exhibits100: Chart on Injection - Market size and forecast 2024-2029 ($ million); Exhibits101: Data Table on Injection - Market size and forecast 2024-2029 ($ million); Exhibits102: Chart on Injection - Year-over-year growth 2024-2029 (%); Exhibits103: Data Table on Injection - Year-over-year growth 2024-2029 (%); Exhibits104: Chart on Transdermal - Market size and forecast 2024-2029 ($ million); Exhibits105: Data Table on Transdermal - Market size and forecast 2024-2029 ($ million); Exhibits106: Chart on Transdermal - Year-over-year growth 2024-2029 (%); Exhibits107: Data Table on Transdermal - Year-over-year growth 2024-2029 (%); Exhibits108: Market opportunity by Route of Administration ($ million); Exhibits109: Data Table on Market opportunity by Route of Administration ($ million); Exhibits110: Chart on End-user - Market share 2024-2029 (%); Exhibits111: Data Table on End-user - Market share 2024-2029 (%); Exhibits112: Chart on Comparison by End-user; Exhibits113: Data Table on Comparison by End-user; Exhibits114: Chart on Hospital pharmacy - Market size and forecast 2024-2029 ($ million); Exhibits115: Data Table on Hospital pharmacy - Market size and forecast 2024-2029 ($ million); Exhibits116: Chart on Hospital pharmacy - Year-over-year growth 2024-2029 (%); Exhibits117: Data Table on Hospital pharmacy - Year-over-year growth 2024-2029 (%); Exhibits118: Chart on Retail pharmacy - Market size and forecast 2024-2029 ($ million); Exhibits119: Data Table on Retail pharmacy - Market size and forecast 2024-2029 ($ million); Exhibits120: Chart on Retail pharmacy - Year-over-year growth 2024-2029 (%)